Unravelling the Politics Behind India’s PM-JAY Health Insurance Scheme

By HEOR Staff Writer

July 26, 2023

The PM-JAY health insurance scheme, launched in India in 2018, was a crucial step towards universal health coverage (UHC). The policy’s design was shaped by a mix of technical and political elements, with a focus on bureaucratic aspects rather than ideological ones. The scheme was introduced by the ruling government just before national elections, leveraging policy legacies from previous and state insurance schemes. Key decisions such as the coverage amount and portability of benefits were centrally driven, while inputs from Indian states influenced features like the mode of implementation and provider network. This balanced approach facilitated the adoption of the reform. However, the scheme’s success hinges on addressing systemic issues and involving all stakeholders. As PM-JAY continues to be implemented, understanding the politics, power dynamics, and structural issues that shaped its formulation will be crucial.

Reference url

Recent Posts

Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local Production Capacity

By João L. Carapinha

May 19, 2026

In a major step forward for vaccine manufacturing Africa, Biovac has secured a financing package from the International Finance Corporation (IFC), the EIB Group, and the European Commission to build the continent’s first end-to-end multi-vaccine production facility. Landmark Funding ...
Healthcare Innovation Trends: Insights from the Healthcare Economics Conference in Lisbon
The conference “Healthcare Economics: Sustainability and Innovation,” held on 5 May in Lisbon and organised by Jornal Económico in partnership with Morais Leitão, brought together experts to explore healthcare innovation trends shaping Portugal’s system. Central discussions focused on financial p...
Pharmaceutical Onshoring Agreements: Navigating Tariff Relief and National Security Policies

By João L. Carapinha

May 18, 2026

The US Bureau of Industry and Security published formal procedures enabling manufacturers of patented pharmaceutical products to apply for company-specific pharmaceutical onshoring agreements with the Department of Commerce. These agreements allow qualifying firms to secure a reduced Section 232 ...